Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

The present disclosure pertains to antimicrobial compounds that include silver (Ag) and an s-triazine ring with substitutions at nitrogen or carbon atoms of the s-triazine ring. In one example, the antimicrobial silver s-triazine may be readily incorporated in a variety of compositions and devices in both medical and non-medical settings. In another example, the said compounds may possess broad spectrum antimicrobial activity against bacteria, viruses, fungi and other microbes.

The present disclosure pertains to antimicrobial compounds that include silver (Ag) and an s-triazine ring with substitutions at nitrogen or carbon atoms of the s-triazine ring. In one example, the antimicrobial silver s-triazine may be readily incorporated in a variety of compositions and devices in both medical and non-medical settings. In another example, the said compounds may possess broad spectrum antimicrobial activity against bacteria, viruses, fungi and other microbes.